Psychopharmacological treatment with risperidone and psychotherapic- rehabilitative approaches in schizophrenia and personality disorders

V. Laini, A. Arduini, E. Critelli, R. Rossetti, L. Mapelli, L. Boscati, F. Regispani, R. Orlandi, P. Papa, M. C. Mauri

Research output: Contribution to journalArticle


20 out-patients, affected by Schizophrenia or Personality Disorders according to DSM-IV, treated with risperidone (RSP) at a mean dosage of 4.46 mg ± 1.35 SD for 12 months, were included in the study. 5 patients also benefitted from psychotherapy, 5 participated in rehabilitation and re- socialisation groups while 10 received psychoeducational/supportive interventions. BPRS and PANSS total score (mean values) showed a significant decrease during the study. No correlation between RSP dosage and RSP or its metabolite, 9 hydroxy-risperidone (9OH-RSP) plasma levels resulted. No linear relationship between RSP plasma levels or active moiety and clinical improvement was observed. RSP therapy facilitated the psychotherapeutic compliance, re-socialisation processes and participation in groups, improving patients quality of life and relational modalities.

Original languageEnglish
Pages (from-to)209-213
Number of pages5
JournalNew Trends in Experimental and Clinical Psychiatry
Issue number4
Publication statusPublished - 1999



  • Psychotherapy-rehabilitative approach
  • Risperidone
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this